Discovery of Azd2716: A Novel Secreted Phospholipase A2 (Spla2) Inhibitor for the Treatment of Coronary Artery Disease
Giordanetto, F., Pettersen, D., Starke, I., Nordberg, P., Dahlstrom, M., Knerr, L., Selmi, N., Rosengren, B., Larsson, L.O., Sandmark, J., Castaldo, M., Dekker, N., Karlsson, U., Hurt-Camejo, E.(2016) ACS Med Chem Lett 7: 884
- PubMed: 27774123 
- DOI: https://doi.org/10.1021/acsmedchemlett.6b00188
- Primary Citation of Related Structures:  
5G3M, 5G3N - PubMed Abstract: 
Expedited structure-based optimization of the initial fragment hit 1 led to the design of ( R )- 7 (AZD2716) a novel, potent secreted phospholipase A 2 (sPLA 2 ) inhibitor with excellent preclinical pharmacokinetic properties across species, clear in vivo efficacy, and minimized safety risk. Based on accumulated profiling data, ( R )- 7 was selected as a clinical candidate for the treatment of coronary artery disease.
Organizational Affiliation: 
Cardiovascular and Metabolic Diseases, Innovative Medicines and Early Development Biotech Unit Departments of Medicinal Chemistry, Bioscience, DMPK, Discovery Sciences Departments of Structure & Biophysics, Reagents and Assay Development, and Screening Sciences and Sample Management, Astrazeneca, Mölndal , Pepparedsleden 1, SE-431 83 Mölndal, Sweden.